IBDEI1WJ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31849,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31849,1,2,0)
 ;;=2^H0005
 ;;^UTILITY(U,$J,358.3,31849,1,3,0)
 ;;=3^Addictions Group Counseling by Clinician
 ;;^UTILITY(U,$J,358.3,31850,0)
 ;;=H0006^^139^1468^5^^^^1
 ;;^UTILITY(U,$J,358.3,31850,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31850,1,2,0)
 ;;=2^H0006
 ;;^UTILITY(U,$J,358.3,31850,1,3,0)
 ;;=3^Alcohol/Drug Case Management
 ;;^UTILITY(U,$J,358.3,31851,0)
 ;;=H0020^^139^1468^8^^^^1
 ;;^UTILITY(U,$J,358.3,31851,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31851,1,2,0)
 ;;=2^H0020
 ;;^UTILITY(U,$J,358.3,31851,1,3,0)
 ;;=3^Methadone Administration &/or Svc by Lincensed Program
 ;;^UTILITY(U,$J,358.3,31852,0)
 ;;=H0025^^139^1468^2^^^^1
 ;;^UTILITY(U,$J,358.3,31852,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31852,1,2,0)
 ;;=2^H0025
 ;;^UTILITY(U,$J,358.3,31852,1,3,0)
 ;;=3^Addictions Health Prevention/Education
 ;;^UTILITY(U,$J,358.3,31853,0)
 ;;=H0030^^139^1468^4^^^^1
 ;;^UTILITY(U,$J,358.3,31853,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31853,1,2,0)
 ;;=2^H0030
 ;;^UTILITY(U,$J,358.3,31853,1,3,0)
 ;;=3^Addictions Hotline Services
 ;;^UTILITY(U,$J,358.3,31854,0)
 ;;=99600^^139^1469^1^^^^1
 ;;^UTILITY(U,$J,358.3,31854,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31854,1,2,0)
 ;;=2^99600
 ;;^UTILITY(U,$J,358.3,31854,1,3,0)
 ;;=3^Case Management at Pts Home
 ;;^UTILITY(U,$J,358.3,31855,0)
 ;;=T1016^^139^1469^2^^^^1
 ;;^UTILITY(U,$J,358.3,31855,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31855,1,2,0)
 ;;=2^T1016
 ;;^UTILITY(U,$J,358.3,31855,1,3,0)
 ;;=3^Case Management per 15min
 ;;^UTILITY(U,$J,358.3,31856,0)
 ;;=96372^^139^1470^1^^^^1
 ;;^UTILITY(U,$J,358.3,31856,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31856,1,2,0)
 ;;=2^96372
 ;;^UTILITY(U,$J,358.3,31856,1,3,0)
 ;;=3^Ther/Proph/Diag Inj SC/IM
 ;;^UTILITY(U,$J,358.3,31857,0)
 ;;=96374^^139^1470^2^^^^1
 ;;^UTILITY(U,$J,358.3,31857,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31857,1,2,0)
 ;;=2^96374
 ;;^UTILITY(U,$J,358.3,31857,1,3,0)
 ;;=3^Ther/Proph/Diag Inj IV Push
 ;;^UTILITY(U,$J,358.3,31858,0)
 ;;=96376^^139^1470^3^^^^1
 ;;^UTILITY(U,$J,358.3,31858,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31858,1,2,0)
 ;;=2^96376
 ;;^UTILITY(U,$J,358.3,31858,1,3,0)
 ;;=3^Tx/Pro/Dx Inj,ea addl sequential IVP of Same Drug-Add-on
 ;;^UTILITY(U,$J,358.3,31859,0)
 ;;=J2680^^139^1471^1^^^^1
 ;;^UTILITY(U,$J,358.3,31859,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31859,1,2,0)
 ;;=2^J2680
 ;;^UTILITY(U,$J,358.3,31859,1,3,0)
 ;;=3^Fluphenazine Decanoate up to 25mg
 ;;^UTILITY(U,$J,358.3,31860,0)
 ;;=J1631^^139^1471^2^^^^1
 ;;^UTILITY(U,$J,358.3,31860,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31860,1,2,0)
 ;;=2^J1631
 ;;^UTILITY(U,$J,358.3,31860,1,3,0)
 ;;=3^Haloperidol Decanoate per 50mg
 ;;^UTILITY(U,$J,358.3,31861,0)
 ;;=J2315^^139^1471^3^^^^1
 ;;^UTILITY(U,$J,358.3,31861,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31861,1,2,0)
 ;;=2^J2315
 ;;^UTILITY(U,$J,358.3,31861,1,3,0)
 ;;=3^Naltrexone,Depot Form 1mg
 ;;^UTILITY(U,$J,358.3,31862,0)
 ;;=J2426^^139^1471^8^^^^1
 ;;^UTILITY(U,$J,358.3,31862,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31862,1,2,0)
 ;;=2^J2426
 ;;^UTILITY(U,$J,358.3,31862,1,3,0)
 ;;=3^Paliperidone Palmitate Extend Release 234mg/kit
 ;;^UTILITY(U,$J,358.3,31863,0)
 ;;=J2426^^139^1471^7^^^^1
 ;;^UTILITY(U,$J,358.3,31863,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31863,1,2,0)
 ;;=2^J2426
 ;;^UTILITY(U,$J,358.3,31863,1,3,0)
 ;;=3^Paliperidone Palmitate Extend Release 156mg/kit
 ;;^UTILITY(U,$J,358.3,31864,0)
 ;;=J2426^^139^1471^6^^^^1
